NZ506153A - Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds - Google Patents

Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds

Info

Publication number
NZ506153A
NZ506153A NZ506153A NZ50615399A NZ506153A NZ 506153 A NZ506153 A NZ 506153A NZ 506153 A NZ506153 A NZ 506153A NZ 50615399 A NZ50615399 A NZ 50615399A NZ 506153 A NZ506153 A NZ 506153A
Authority
NZ
New Zealand
Prior art keywords
cmt
tetracycline
mmp
dimethylamino
activity
Prior art date
Application number
NZ506153A
Other languages
English (en)
Inventor
Lorne M Golub
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of NZ506153A publication Critical patent/NZ506153A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ506153A 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds NZ506153A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/052,222 US6277061B1 (en) 1998-03-31 1998-03-31 Method of inhibiting membrane-type matrix metalloproteinase
PCT/US1999/006972 WO1999049871A1 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Publications (1)

Publication Number Publication Date
NZ506153A true NZ506153A (en) 2003-10-31

Family

ID=21976191

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506153A NZ506153A (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds

Country Status (8)

Country Link
US (2) US6277061B1 (cg-RX-API-DMAC7.html)
EP (1) EP1079837A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002509889A (cg-RX-API-DMAC7.html)
KR (1) KR20010042322A (cg-RX-API-DMAC7.html)
AU (1) AU748870B2 (cg-RX-API-DMAC7.html)
CA (1) CA2320260A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ506153A (cg-RX-API-DMAC7.html)
WO (1) WO1999049871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
WO2003030819A2 (en) * 2001-10-05 2003-04-17 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003082011A1 (en) * 2002-03-29 2003-10-09 The Research Foundation Of State University Of New York Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Rnaを調節するための置換テトラサイクリン化合物の使用方法
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド 9−アミノメチルテトラサイクリン化合物のプロドラッグ
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 4−アミノテトラサイクリンおよびその使用の方法
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
LT2707003T (lt) 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
AU3457699A (en) 1999-10-18
US6277061B1 (en) 2001-08-21
US20020045603A1 (en) 2002-04-18
WO1999049871A8 (en) 1999-12-02
CA2320260A1 (en) 1999-10-07
AU748870B2 (en) 2002-06-13
JP2002509889A (ja) 2002-04-02
WO1999049871A1 (en) 1999-10-07
EP1079837A4 (en) 2003-07-02
EP1079837A1 (en) 2001-03-07
KR20010042322A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
AU729886B2 (en) Method of inhibiting cancer growth
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
Johnson et al. Matrix metalloproteinases
ES2241124T3 (es) Actividad inhibidora de serin-proteinasa mediante tetraciclina hidrofoba.
Vartak et al. Matrix metalloproteases: underutilized targets for drug delivery
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
Davies et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
Cockett et al. Matrix metalloproteinases and metastatic cancer
ES2578618T3 (es) Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
EP0671942B1 (en) Pharmaceutical preparation comprising a beta-lactam antibiotic degrading compound, and use thereof
Lee et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer
US20090269405A1 (en) Enzyme mediated delivery system
US20050220780A1 (en) Pharmaceutical composition having thrombolytic anti-inflammatory and cytoprotective properties
US6429204B1 (en) Method of inhibiting cancer growth
JP2005535674A (ja) 線維症および瘢痕形成の治療におけるコンバターゼインヒビターの使用
Hanemaaijer et al. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines
Rathna et al. Recent Insights of Matrix Metalloproteinase Inhibitors in Therapeutic Applications
Frimodt-Möller et al. Co-trimazine distribution in the canine prostate
MXPA99006554A (en) Method of inhibiting cancer growth
Acid Correlation of Antiangiogenic and Antitumor Efficacy of
Cawston Mechanisms of Joint Destruction and Therapeutic Approaches

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)